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1. introduction 
Affinity chromatography using vitamin Bra (Bra) 
covalently coupled to Sepharose has been used to 
isolate from solution a number of Bra-binding pro- 
teins including gastric intrinsic factor (IF) [ 1,2] . The 
procedure requires the use of concentrated guanidine- 
HCl, a known protein denaturant, o dissociate the 
binding protein from the Bra-Sepharose complex. 
The Bra-binding proteins, like other ligand-binding 
transport macromolecules, are structurally bifunc- 
tional; that is, there are two biologically important 
reacting sites, one which binds the ligand-substrate 
and the second which attaches to a receptor site on 
the cell. When such a binding protein is isolated by 
affinity chromatography using the ligandsubstrate 
coupled to the solid matrix, the ligand binding site on 
the macromolecule becomes tructurally fured, whereas 
the receptor binding site remains exposed and more 
susceptible to chemical alteration. This report will 
present evidence that human gastric intrinsic factor 
purified by elution from Bra-Sepharose column by 
7.5 M guanidine-HCl, although structurally homo- 
geneous by disc-gel electrophoresis,  nevertheless 
different than the native IF in gastric juice because 
there is decreased affinity for the intestinal receptor. 
2. Materials and methods 
2.1. Purrfication of human IF by affinity chromato- 
gmphy 
Human IF was purified by affinity chromatography 
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according to the method of Allen et al. [2]. Briefly, 
normal human gastric juice (NHGJ) obtained by naso- 
gastric suction after pentogastrin stimulation [3] was 
applied to an affinity resin composed of vitamin Bra 
covalently coupled to Sepharose beads (Pharmacia 
Fine Chemicals) via a six carbon (3,3’-diaminodipro- 
pylamine) spacer group. After thorough washing of 
the resin with 0.1 M Tris-acetate, pH 9.2,0.1 M 
glycine-NaOH, pH 10, containing 0.1 M glucose and 
1 .O M NaCl and 0.1 M potassium phosphate, pH 7.5, 
IF was eluted by exposure of the resin to 7.5 M 
guanidine-HCl in 0.1 M potassium phosphate, pH 7.5, 
for 1 h. A longer period of exposure to guanidine- 
HCl(18 h) is required to dissociate the R-type Bra 
binder in gastric juice. The fraction containing the IF 
was then dialyzed against 7.5 M guanidine-HCl for 
48 h and then against water, after addition to the 
sample of a three-fold excess of cyan0 [“Co]cobalamin 
([“CoJBra) (0.01 @i/pg) (Amersham/Searle Corp.). 
A fraction of the purified IF was dialyzed against 
water which contained no Bra and this is referred to 
as unsaturated IF. Disc-gel electrophoresis [4] of the 
final preparation showed one protein band. Similar 
electrophoresis of a sample saturated with [“Co] Bra 
and iodinated with-r2’I using chloramine T [5] demon- 
strated that the [57Co]B12 and “‘1 peak moved 
together through the gel. 
The Br2 binding capacity of the purified unsatu- 
rated IF was determined by incubating an aliquot of 
the preparation with a saturating amount of [“‘Co] B 12 
for 30 min and then precipitating the bound vitamin 
using ZnS04 Ba(OH)2 as described previously [6] . 
The interaction of the purified IF with blocking 
(type I) and binding (type II) anti-IF antibody was 
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determined by the method of Rothenberg et al. [7] 
using the serum from a patient with pernicious anemia 
as the source of both types of antibody. The same 
radioassay procedure was used to measure the amount 
of Blz specifically bound to IF in NHGJ. 
The interaction of the purified IF with the recep- 
tor protein prepared from the guinea-pig leal mucosa 
was determined by the method of Cotter and 
Rothenberg [8]. 
3. Results 
There was a distinct difference in the interaction 
of the purified IF with excess blocking and binding 
anti-IF antibody as shown by the data in table 1. 
Whereas approximately 84% of the B1? binding was 
blocked by preincubating the IF with the antiserum, 
only 42% (30 min incubation at 22’C) to 54% (18 h 
incubation at 4’C) of IF-bound [“CO]B~~ precipitated 
with the binding antibody. The ratio of binding to 
blocking antibody reaction was approximately 0.5 for 
the 30 min incubation. Similar reactions with this anti- 
serum and native IF gave a binding to blocking ratio 
of 1.13. It is evident from these results that the 
moiety on the IF molecule which reacts with the 
binding antibody and which is distant from the Blz 
binding site is altered by the purification procedure. 
The fact that immunoreactivity with the binding anti- 
body increases 29% over 18 h as compared to only a 
3% increase with the blocking antibody reaction, 
indicates adecreased affinity for the binding antibody 
Table 2 
Binding of native IF and purified IF by receptor protein 
from guinea-pig ileum 
Binding to receptor 
Substrate % Pga 
[“Co]B,, (65 pg) native IFb 67.1 43.6 
[“Co]B,, (62.5 pg) purified IF 39.5 24.7 
aIndicates pg of IF bound [57Co]B,, - each value is the 
mean of duplicate reactions 
bAmount of [“CO]B,~ bound to IF in NHGJ was determined 
by radioimmunoassay [ 71 
site, and is further evidence for a structural alteration 
of this moiety of the IF molecule. Normally, the 
binding of native IF by excess antiserum reaches 90% 
or more of maximum in 30 min. 
The binding of the purified IF saturated with 
[57Co] Blz to a preparation of guinea-pig leum recep- 
tor protein was compared to the binding of the same 
amount of IF- [57Co] B1? in NHGJ. Table 2 shows that 
the receptor preparation bound 67.1%, or 43.6 pg of 
the [“CO]B~~ bound to native IF in NHGJ, whereas 
the receptor bound only 39.5%, or 26.6 pg of 
[“Co]B12 bound to the purified IF. 
The relative affinity of the purified IF and native 
IF in gastric juice for the ileal receptor protein was 
also determined by measuring the competitive ffect 
of each on the receptor binding of native IF-[“Co]B12 
The graph in fig.1 shows that the purified IF is much 
less competitive than equimolar amounts of native IF 
Table 1 
Reaction of the purified IF and native IF with blocking and binding 
anti-IF antibody 




30 min incubation 22°C 82 42 0.51 
18 h incubation 4’C 84 54 0.64 
Native IF in NHGJC 
30 min incubation 22’C 68 77 1.13 
a% Total [ 57Co] B 1a binding which is blocked by preincubation with the antiserum 
b% Total bound [ 5’C]B,, which is precipitated after incubation with the antiserum 
cWith this sample of NHGJ, the % blocking and binding is reduced because 
approximately 30% of the [S’Co]B,, Is bound by non-IF binder(s) 
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Fig.1. The competitive effect of equimolar ccncentrations ofpurified IF-B,, (mean f SD of triplicate determinations) and native 
IF-B,, (mean f SD of seven different samples of gastric juice) on the binding of native IF-[“Co]B,, (100 pg [5’Co]B,,) by 
parGaIly purified intestinal IF receptor protein from the guinea-pig ileum. The B,, binding capacity of the purified IF was 
determined by titrating the binding of [5’Co]B,,. The B,, binding capacity of IF in gastric juice was determined by the amount of 
[ S’Co]B,, specifically precipitated by anti-IF antibody [ 71. Each preparation was then saturated with excess unlabeled B,, and 
dialyzed overnight to remove the unbound vitamin. The ordinate was normalized such that the amount of IF-[5’Co]B,, bound to 
receptor in the absence of native IF or purified IF was 100%. 
(both saturated with unlabeled Brz) on the binding of 
native IF-[“Co]Br2 to the receptor. 
4. Discussion 
These data indicate that during the course of affi- 
nity purification of human IF using 7.5 M guanidine- 
HCl, a structural alteration has occurred on that 
moiety of the molecule which interacts with the 
binding antibody and the intestinal IF receptor protein 
with only slight alteration on that part of the mole- 
cule which binds to vitamin Br2 and blocking antibody. 
It would seem likely that while the IF is bound to 
the immobilized Br2--Sepharose, the B12 binding site 
(which is also in close proximity to the site which 
binds to blocking antibody) is protected from the 
denaturing effects of the guanidine, whereas the more 
exposed moiety of the IF molecule, which is the 
reactive site for binding to the intestinal receptor protein 
(or binding type anti-IF antibody), is unprotected by 
ligand attachment and is structurally altered by the 
guanidine. 
It is evident that when a protein has two functional 
moieties, such as a substrate binding site and a recep- 
tor binding site, purification by affinity chromato- 
graphy using strong denaturant chemicals can selec- 
tively alter the unassociated (or free) binding site. This 
may not be appreciated if the structural integrity of 
the molecule is determined only by its capacity to bind 
to the ligand to which it was attached during the 
purification procedure. Studies, therefore, to evaluate 
the biologic function of the free binding site must be 
interpreted cautiously since the protein may not be 
truly representative of the function of the native mole- 
cule. 
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